AU2012282077A1 - Stable dosage forms of arterolane and piperaquine - Google Patents
Stable dosage forms of arterolane and piperaquine Download PDFInfo
- Publication number
- AU2012282077A1 AU2012282077A1 AU2012282077A AU2012282077A AU2012282077A1 AU 2012282077 A1 AU2012282077 A1 AU 2012282077A1 AU 2012282077 A AU2012282077 A AU 2012282077A AU 2012282077 A AU2012282077 A AU 2012282077A AU 2012282077 A1 AU2012282077 A1 AU 2012282077A1
- Authority
- AU
- Australia
- Prior art keywords
- dosage form
- active compound
- piperaquine
- solid oral
- stable solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229950006717 piperaquine Drugs 0.000 title claims abstract description 82
- UCRHFBCYFMIWHC-UHFFFAOYSA-N piperaquine Chemical compound ClC1=CC=C2C(N3CCN(CC3)CCCN3CCN(CC3)C=3C4=CC=C(C=C4N=CC=3)Cl)=CC=NC2=C1 UCRHFBCYFMIWHC-UHFFFAOYSA-N 0.000 title claims abstract description 81
- 239000002552 dosage form Substances 0.000 title claims abstract description 50
- BRJULSXZDFYSPG-MSMJXPJBSA-N CC(C)(N)NC(=O)C[C@H]1CC[C@]2(CC1)OOC1(O2)[C@H]2CC3CC(C2)C[C@H]1C3 Chemical compound CC(C)(N)NC(=O)C[C@H]1CC[C@]2(CC1)OOC1(O2)[C@H]2CC3CC(C2)C[C@H]1C3 BRJULSXZDFYSPG-MSMJXPJBSA-N 0.000 title description 2
- 229950007854 arterolane Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 130
- 239000006186 oral dosage form Substances 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 51
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 48
- 230000008569 process Effects 0.000 claims abstract description 28
- 238000001035 drying Methods 0.000 claims abstract description 11
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims abstract description 10
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims description 49
- 239000007787 solid Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 47
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 36
- 239000008187 granular material Substances 0.000 claims description 33
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 28
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 28
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 28
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 27
- 201000004792 malaria Diseases 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 21
- 239000000314 lubricant Substances 0.000 claims description 21
- 239000003085 diluting agent Substances 0.000 claims description 19
- 235000019359 magnesium stearate Nutrition 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 17
- 238000000576 coating method Methods 0.000 claims description 17
- 239000007884 disintegrant Substances 0.000 claims description 17
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 12
- 238000011049 filling Methods 0.000 claims description 12
- 229960000913 crospovidone Drugs 0.000 claims description 11
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 11
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 238000007908 dry granulation Methods 0.000 claims description 5
- 239000008184 oral solid dosage form Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 238000007907 direct compression Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000009490 roller compaction Methods 0.000 claims description 3
- 238000009491 slugging Methods 0.000 claims description 3
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 239000011247 coating layer Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- 239000003605 opacifier Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 description 30
- 229940079593 drug Drugs 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 229940000425 combination drug Drugs 0.000 description 20
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 19
- 239000003430 antimalarial agent Substances 0.000 description 18
- 244000045947 parasite Species 0.000 description 18
- -1 chloroproguanil Chemical compound 0.000 description 16
- 239000007909 solid dosage form Substances 0.000 description 16
- 230000000078 anti-malarial effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 10
- 229930101531 artemisinin Natural products 0.000 description 10
- SWMNGXODFOCPKQ-BTJKTKAUSA-N (z)-but-2-enedioic acid;n'-methoxy-4-[5-[4-[(z)-n'-methoxycarbamimidoyl]phenyl]furan-2-yl]benzenecarboximidamide Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C(=N)NOC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NOC)O1 SWMNGXODFOCPKQ-BTJKTKAUSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 229960004191 artemisinin Drugs 0.000 description 9
- 125000003003 spiro group Chemical group 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241000223960 Plasmodium falciparum Species 0.000 description 8
- RZYIPLSVRHWROD-UHFFFAOYSA-N 1,2,4-trioxolane Chemical compound C1OCOO1 RZYIPLSVRHWROD-UHFFFAOYSA-N 0.000 description 7
- 241000157855 Cinchona Species 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 229960001681 croscarmellose sodium Drugs 0.000 description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- DYLGFOYVTXJFJP-MYYYXRDXSA-N lumefantrine Chemical compound C12=CC(Cl)=CC=C2C=2C(C(O)CN(CCCC)CCCC)=CC(Cl)=CC=2\C1=C/C1=CC=C(Cl)C=C1 DYLGFOYVTXJFJP-MYYYXRDXSA-N 0.000 description 6
- 229960004985 lumefantrine Drugs 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 235000001258 Cinchona calisaya Nutrition 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 229960000948 quinine Drugs 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 4
- 241000255925 Diptera Species 0.000 description 4
- 241000237858 Gastropoda Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010029350 Neurotoxicity Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000035999 Recurrence Diseases 0.000 description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229960003677 chloroquine Drugs 0.000 description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 239000007891 compressed tablet Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000002688 maleic acid derivatives Chemical class 0.000 description 4
- 231100000228 neurotoxicity Toxicity 0.000 description 4
- 230000007135 neurotoxicity Effects 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000007935 oral tablet Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000000973 gametocyte Anatomy 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 229960001962 mefloquine Drugs 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 210000003046 sporozoite Anatomy 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- LUBUTTBEBGYNJN-UHFFFAOYSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC LUBUTTBEBGYNJN-UHFFFAOYSA-N 0.000 description 2
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
- BJDCWCLMFKKGEE-KDTBHNEXSA-N Dihydroartemisinin (DHA) Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](O)[C@@H]4C BJDCWCLMFKKGEE-KDTBHNEXSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000223810 Plasmodium vivax Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930182558 Sterol Chemical class 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229940081735 acetylcellulose Drugs 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229960001444 amodiaquine Drugs 0.000 description 2
- 229940033495 antimalarials Drugs 0.000 description 2
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 2
- 229960003159 atovaquone Drugs 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 229960000860 dapsone Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 239000013561 fixed dose combination tablet Substances 0.000 description 2
- GJXWDTUCERCKIX-UHFFFAOYSA-N fosmidomycin Chemical compound O=CN(O)CCCP(O)(O)=O GJXWDTUCERCKIX-UHFFFAOYSA-N 0.000 description 2
- 229950006501 fosmidomycin Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 210000003936 merozoite Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229960005385 proguanil Drugs 0.000 description 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005563 spheronization Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- MAAKQSASDHJHIR-UHFFFAOYSA-N trioxolane Chemical class C1COOO1 MAAKQSASDHJHIR-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- UYVWNPAMKCDKRB-UHFFFAOYSA-N 1,2,4,5-tetraoxane Chemical class C1OOCOO1 UYVWNPAMKCDKRB-UHFFFAOYSA-N 0.000 description 1
- 150000004903 1,2,4-trioxanes Chemical class 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000256182 Anopheles gambiae Species 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 235000021513 Cinchona Nutrition 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HDIFHQMREAYYJW-XGXNLDPDSA-N Glyceryl Ricinoleate Chemical class CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-XGXNLDPDSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- QCNVFAQSXRNCES-UHFFFAOYSA-L S(=O)(=O)(O)C(C(=O)OCCCCCCCC)CC(=O)[O-].[Na+].[Na+].C(CCCCCCC)OC(C(CC(=O)[O-])S(=O)(=O)O)=O Chemical compound S(=O)(=O)(O)C(C(=O)OCCCCCCCC)CC(=O)[O-].[Na+].[Na+].C(CCCCCCC)OC(C(CC(=O)[O-])S(=O)(=O)O)=O QCNVFAQSXRNCES-UHFFFAOYSA-L 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- KTXOMTYYRXOZPI-UHFFFAOYSA-N [Na].CCCCCCCCCCCC[Na] Chemical compound [Na].CCCCCCCCCCCC[Na] KTXOMTYYRXOZPI-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 229940013915 artesunate and amodiaquine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000012494 forced degradation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940116338 glyceryl ricinoleate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 108010080417 hemozoin Proteins 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003108 parasitologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 229930183339 qinghaosu Natural products 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 239000003421 short acting drug Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- UDWXLZLRRVQONG-UHFFFAOYSA-M sodium hexanoate Chemical compound [Na+].CCCCCC([O-])=O UDWXLZLRRVQONG-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The field of the invention relates to stable oral dosage forms comprising, (a) cis-adamantane-2-spiro-3'-8'-[[[(2'-amino-2'-methylpropyl) amino]carbonyl]-methyl]-l',2',4'-trioxaspiro[4.5]decane hydrogen maleate (Active compound I); (b) piperaquine; and (c) one or more pharmaceutically acceptable excipients; and processes for their preparation, especially wherein the dosage form is prepared by a dry process.
Description
WO 2013/008218 PCT/IB2012/053614 STABLE DOSAGE FORMS OF ARTEROLANE AND PIPERAQUINE Field of the Invention The field of the invention relates to stable oral dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues and processes for their preparation. Background of the Invention Malaria, the most common parasitic disease of humans, remains a major health and economic burden in most tropical countries. Large areas of Central and South America, Hispaniola (Haiti and the Dominican Republic), Africa, the Middle East, the Indian subcontinent, Southeast Asia, and Oceania are considered as malaria-risk areas. It leads to a heavy toll of illness and death, especially amongst children and pregnant women. According to the World Health Organization, it is estimated that the disease infects about 400 million people each year, and around two to three million people die from malaria every year. There are four kinds of malaria parasites that infect human: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae. Malaria spreads from one person to another by the bite of mosquito, Anopheles gambiae, which serves as vector. When a mosquito sucks the blood of human, sporozoites are transfused into the human body together with saliva of the mosquito. The sporozoites enter into the hepatocytes, reproduce asexually and finally enter into the blood stream. The parasites continue to multiply inside the red blood cells, until they burst and release large number of merozoites. This process continues, destroying a significant number of blood cells and causing the characteristic paroxysm ("chills and fever") associated with the disease. In the red blood cells, some of the merozoites become male or female gametocytes. These gametocytes are ingested by the mosquito when it feeds on blood. The gametocytes fuse in the vector's gut; sporozoites are produced and are migrated to the vector's salivary glands. The clinical symptoms of malaria are generally associated with the bursting of red blood cells causing an intense fever associated with chills that can leave the infected individual exhausted and bedridden. More severe symptoms associated with repeat WO 2013/008218 PCT/IB2012/053614 2 infections and/or infection by Plasmodium falciparum include anaemia, severe headaches, convulsions, delirium and, in some instances, death. Quinine, an antimalarial compound that is extracted from the bark of cinchona tree, is one of the oldest and most effective drugs in existence. Chloroquine and mefloquine are 5 the synthetic analogs of quinine developed in 1940's, which due to their effectiveness, ease of manufacture, and general lack of side effects, became the drugs of choice. The downside to quinine and its derivatives is that they are short-acting and have bitter taste. Further, they fail to prevent disease relapses and are also associated with side effects commonly known as "Chinchonism syndrome" characterized by nausea, vomiting, 10 dizziness, vertigo and deafness. However, in recent years, with the emergence of drug resistant strains of parasite and insecticide-resistant strains of vector, the treatment and/or control of malaria is becoming difficult with these conventional drugs. Malarial treatment further progressed with the discovery of Artemisinin (qinghaosu), a naturally occurring endoperoxide sesquiterpene lactone isolated from the 15 plant Artemisia annua (Meshnick et al., Microbiol. Rev. 1996, 60, p. 301-315; Vroman et al., Curr. Pharm. Design, 1999, 5, p. 101-138; Dhingra et al., 2000, 66, p. 279-300), and a number of its precursors, metabolites and semi-synthetic derivatives which have shown to possess antimalarial properties. The antimalarial action of artemisinin is due to its reaction with iron in free heme molecules of the malaria parasite, with the generation of free 20 radicals leading to cellular destruction. This initiated a substantial effort to elucidate its molecular mechanism of action (Jefford, dv. Drug Res. 1997, 29, p. 271-325; Cumming et al., Adv. Pharmacol. 1997, 37, p. 254-297) and to identify novel antimalarial peroxides (Dong and Vennerstrom, Expert Opin. Ther. Patents 2001, 11, p. 1753-1760). Although the clinically useful artemisinin derivatives are rapid acting and potent 25 antimalarial drugs, they have several disadvantages including recrudescence, neurotoxicity, (Wesche et al., Antimicrob. Agents. Chemother. 1994, 38, p. 1813-1819) and metabolic instability (White, Trans. R. Soc. Trop. Med. Hyg., 1994, 88, p. 41-43). A fair number of these compounds are quite active in vitro, but most suffer from low oral activity (White, Trans. R. Soc. Trop. Med. Hyg., 1994, 88, p. 41-43 and van Agtmael et 30 al., Trends Pharmacol. Sci., 1999, 20, p. 199-205).
WO 2013/008218 PCT/IB2012/053614 3 Further all these artemisinin derivatives are conventionally obtained from plant source and are therefore expensive. As the cultivation of the plant material is dependent on many factors including the weather conditions, the supply source thus becomes finite and there are chances of varying yield and potency. This leads to quality inconsistencies and 5 supply constraints. As malaria is more prevalent in developing countries, a switch to cheaper and effective medicine is highly desirable. Thus there exists a need in the art to identify new peroxide antimalarial agents, especially those which are not dependent on plant source and can be easily synthesized, are devoid of neurotoxicity, and which possess improved solubility, stability and 10 pharmacokinetic properties. Following that, many synthetic antimalarial 1,2,4-trioxanes (Jefford, Adv. Drug Res. 1997, 29, p. 271-325; Cumming et al., Adv. Pharmacol. 1997, 37, p. 254-297), 1,2,4,5-tetraoxanes (Vennerstrom et al., J. Med. Chem., 2000, 43, p. 2753-2758), and other endoperoxides have been prepared. Various patents/applications disclose means and 15 method for treating malaria using Spiro or dispiro 1,2,4-trioxolanes for example, U.S. Patent Application No. 2004/0186168 and U.S. Patent Nos. 6,486,199 and 6,825,230. The present invention relates to solid dosage forms of the various spiro or dispiro 1,2,4 trioxolanes antimalarial compounds disclosed in these patents/applications and are incorporated herein by reference. 20 Active compounds representing various Spiro and dispiro 1,2,4-trioxolane derivatives possess excellent potency, efficacy against Plasmodium parasites, and a lower degree of neurotoxicity, in addition to their structural simplicity and ease of synthesis. Furthermore, these compounds have half-lives which are believed to permit short-term treatment regimens comparing favorably to other artemisinin-like drugs. In general, the 25 therapeutic dose of trioxolane derivative may range between about 0.1-1000 mg/kg/day, in particular between about 1-100 mg/kg/day. The foregoing dose may be administered as a single dose or may be divided into multiple doses. For malaria prevention, a typical dosing schedule could be, for example, 2.0-1000 mg/kg weekly beginning 1-2 weeks prior to malaria exposure, continued up to 1-2 weeks post-exposure. 30 Monotherapy with artemisinin (natural or synthetic) class of drugs might cure the patients within 3 days, however perceiving the potential threat of the malarial parasite WO 2013/008218 PCT/IB2012/053614 4 developing resistance towards otherwise very potent artemisinin class of drugs, WHO had strictly called for an immediate halt to the provision of single-drug artemisinin malaria pills. Combination therapy in case of malaria retards the development of resistance, improve efficacy by lowering recrudescence rate, provides synergistic effect, and increase 5 exposure of the parasite to the drugs. Artemsinin based combinations are available in the market for a long time. Artemether-lumafentrine (Co-artem@) was the first fixed dose antimalarial combination containing an artemisinin derivative and has been known since 1999. This combination has passed extensive safety and efficacy trials and has been approved by more than 70 10 regulatory agencies. Co-artem@ is recommended by WHO as the first line treatment for uncomplicated malaria. Other artemisinin based combinations include artesunate and amodiaquine (Coarsucam®), and dihydroartemisin and piperaquine (Eurartesim®). Unfortunately, all the available artemisinin based combinations have complicated dosage regimens making it 15 difficult and inconvenient for a patient to comply completely with the total prescribed duration. For example, the dosage regimen of Co-artem® for an adult having body weight of more than 35 kg includes 6 doses over three days. The first dose comprises four tablets initially, the second dose comprises four tablets after eight hours, the third to sixth doses comprise four tablets twice for another two days; making it a total of 24 tablets. The 20 dosage regimen of Coarsucam® for an adult having body weight of more than 36 kg or age above 14 years includes three doses over three days; each dose comprises two tablets; making it a total of six tablets. The dosage regimen of Eurartesim® for an adult having body weight between 36 kg - 75 kg includes 3 doses over three days, each dose comprises of three tablets, making it a total of nine tablets. 25 It is evident that the available artemisinin-based combinations have a high pill burden on patients as they need to consume too many tablets. As noted above, this may increase the possibility of missing a few doses, and, consequently, could result in reduced efficacy due to non-compliance and may even lead to development of resistance for the drug.
WO 2013/008218 PCT/IB2012/053614 5 Therefore, there is an urgent and unmet need for anti-malarial combinations with a simplified daily dosing regimen that reduces the pill burden and would increase patient compliance. Apart from simplifying the regimen, there are certain limitations for formulators 5 developing formulations with trioxolones, the first being their susceptibility to degradation in presence of moisture that results in reduced shelf lives. Another is their bitter taste, which can result in poor compliance of the regimen or selection of another, possibly less effective, therapeutic agent. We have now discovered that a stable antimalarial oral solid dosage form 10 comprising spiro or dispiro 1,2,4-trioxolanes can be prepared by controlling the water content below a certain critical limit. Further, the bitter taste can be masked by applying a film coating layer to the solid dosage form. Summary of the Invention In one general aspect there is provided a stable solid oral dosage form that includes 15 a therapeutically effective amount of a compound having the structural Formula I, 0-0 R1 O R2 Formula I and its enantiomers, diastereomers, polymorphs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates, wherein: 20 R 1 and R 2 are same or different and are selected from hydrogen, substituted or unsubstituted linear or branched alkyl, aryl, and alkaryl groups and substituted or unsubstituted alicyclic groups that are optionally interrupted by one or more oxygen, sulfur or nitrogen atoms, substituted or unsubstituted aromatic or heterocyclic groups that may be interrupted by one or more oxygen, sulfur or nitrogen atoms, a hydroxy group, and 25 a halogen, and further providing that the spirocyclohexyl rings attaching R 1 and R2 are optionally interrupted by one or more oxygen, sulfur, or nitrogen atoms; and one or more pharmaceutically acceptable excipients, wherein not more than 5% w/w total related WO 2013/008218 PCT/IB2012/053614 6 substances are formed on storage at 40'C ± 2 0 C and 75% ± 5% relative humidity over a period of 6 months. Embodiments of the solid oral dosage form may include one or more of the following features. For example, the dosage form may include one or more of other 5 antimalarial drugs. The other antimalarial drugs may include quinine, mefloquine, lumefantrine, sulfadoxine-pyrimethamine, dihydroartimisinin, piperaquine, chloroquine, amodiaquine, proguanil, atovaquone, chloroproguanil, dapsone, fosmidomycin, tetracycline, DB 289 (pafuramidine maleate), clindamycin, or their salts and derivatives thereof. In particular, piperaquine, lumefantrine and DB 289 may be used. 10 In another general aspect, there is provided a method of treatment of malaria. The method includes administering a solid dosage form that includes a therapeutically effective amount of a compound of structural Formula I; and one or more pharmaceutically acceptable excipients, wherein not more than 5% w/w total related substances are formed on storage at 40'C + 2 0 C and 75% + 5% relative humidity over a period of 6 months. 15 In another aspect, there is provided a method of treatment of malaria, wherein the method includes administering a solid dosage form that includes a therapeutically effective amount of a compound of structural Formula I, formulated using a dry or non-aqueous process. In another aspect, there is provided a stable solid oral dosage form, wherein the 20 dosage form includes a therapeutically effective amount of a compound of structural Formula I; at least one other antimalarial drug selected from lumefantrine, piperaquine, or DB 289; and one or more pharmaceutically acceptable excipients. Embodiments of the oral dosage form may include one or more of the following features. For example, the water content of the dosage form may not be more than 6.5% 25 w/w. In another general aspect, there is provided a stable oral solid dosage form comprising cis-adamantane-2-spiro-3'-8'-[[[(2'-amino-2'-methylpropyl) amino]carbonyl] methyl]-l',2',4'-trioxaspiro[4.5]decane hydrogen maleate; piperaquine; and one or more pharmaceutically acceptable excipients. 30 In another general aspect, there is provided a stable solid oral dosage form comprising; WO 2013/008218 PCT/IB2012/053614 7 (a) cis-adamantane-2-spiro-3'-8'-[[[(2'-amino-2' methylpropyl)amino]carbonyl]-methyl]-l',2',4'-trioxaspiro[4.5]decane hydrogen maleate (Active compound I); (b) piperaquine; and 5 (c) one or more pharmaceutically acceptable excipients wherein the dosage form is prepared by a dry process. In another general aspect, there is provided a stable solid oral dosage form comprising; (a) Active compound I; and 10 (b) piperaquine wherein the total drug content is within the range of from about 25% to about 85% w/w based on the total weight of the dosage form. In another general aspect, there is provided a stable solid oral dosage form comprising; 15 (a) Active compound I in an amount of from about 5% to about 25%; and (b) piperaquine in an amount of from about 40% to about 80%, w/w based on the total weight of the dosage form. In another general aspect, there is provided a stable solid oral dosage comprising; (a) Active compound I in an amount of from about 5% to about 25 %; and 20 (b) piperaquine in an amount of from about 40% to about 80% wherein the total drug content does not exceed 85% w/w based on the total weight of the dosage form. In another general aspect, there is provided a stable solid oral dosage of Active compound I and piperaquine; wherein the dosage form has dissolution performance such 25 that more than 7 0% w/w of the Active compound I dissolves within 45 minutes, in a pH 4.5 acetate buffer with 2% tween 80, in USP type II apparatus. In another general aspect, there is provided a stable solid oral dosage form comprising; WO 2013/008218 PCT/IB2012/053614 8 (a) Active compound I and (b) piperaquine; in a weight ratio of about 1:1 to about 1:10. In another general aspect, there is provided a stable oral solid dosage form comprising Active compound I present in a dose range of about 100 to about 300 mg and 5 piperaquine present in a dose range of about 700 mg to about 850 mg. In another general aspect, there is provided a stable solid oral dosage form comprising; (a) Active compound I in an amount of from about 5% to about 25%; (b) piperaquine in an amount of from about 40% to about 80%; 10 (c) diluent in an amount of from about 10% to about 40%; (d) disintegrant in an amount of from about 1% to about 10%; and (e) lubricant in an amount of from about 1% to about 5%; w/w based on the total weight of the dosage form. In another general aspect, there is provided a stable solid oral dosage form 15 comprising; (a) Active compound I; (b) piperaquine; (c) microcrystalline cellulose; (d) crospovidone; and 20 (e) magnesium stearate. In another general aspect there is provided a stable oral solid dosage comprising; (a) Active compound I in an amount of from about 5% to about 2 5 %; (b) piperaquine in an amount of from about 40% to about 80%; and (c) microcrystalline cellulose in an amount of from about 10% to about 40%; 25 w/w based on the total weight of the dosage form.
WO 2013/008218 PCT/IB2012/053614 9 In another general aspect, there is provided a stable solid oral dosage form comprising Active compound I and microcrystalline cellulose in a weight ratio of about 1:1 to about 1:5. The pharmaceutically acceptable excipients may be selected from the group 5 consisting of binders, diluents, glidants/lubricants, disintegrants, surfactants and coloring agents. The solid dosage form may be in the form of a tablet, capsule, pellet, pill, granule or powder. Particularly the dosage form is a tablet or a capsule. More particularly, the dosage form is a tablet. 10 In another general aspect, there is provided a stable solid oral dosage form, wherein the dosage form is processed and stored at a temperature below 27'C and relative humidity 50%. Embodiments of the process may include one or more of the following features. For example, the dosage form is formulated using a dry or non-aqueous process. The non 15 aqueous process may include a non-aqueous granulating liquid selected from ethanol, isopropyl alcohol, acetone, or dichloromethane for preparing the binder solution. The dry process may include direct compression or dry granulation. Dry granulation may be compaction or slugging. In particular, the dry granulation may be compaction for example, dry roller compaction. 20 In another general aspect, there is provided a process for the preparation of a stable solid oral dosage form, comprising the steps of; (a) blending Active compound I, piperaquine, and one or more intragranular excipients; (b) milling, grinding or sieving the blend by roller compaction to form 25 granules; (c) blending the granules with one or more extragranular excipients; (d) compressing the blend into tablets or filling into capsules. In another general aspect, there is provided a process for the preparation of a stable solid oral dosage form, comprising the steps of; WO 2013/008218 PCT/IB2012/053614 10 (a) blending Active compound I, piperaquine, and one or more intragranular excipients; (b) granulating the blend by slugging; (c) blending the granules with one or more extragranular excipients; 5 (d) compressing the blend into tablets or filling into capsules. In another general aspect, there is provided a process for the preparation of a stable solid oral dosage form, comprising the steps of; (a) blending Active compound I, piperaquine, and one or more pharmaceutically acceptable excipients; and 10 (b) directly compressing the blend into tablets or filling into capsules. In another general aspect, there is provided a process for the preparation of a stable solid oral dosage form, comprising the steps of; (a) granulating a blend of one or more excipients; (b) drying the excipient granules; 15 (c) blending excipient granules with Active compound I and piperaquine; and (d) compressing the blend into tablets or filling into capsules. The tablet may be coated with layer(s) of one or more film forming polymers. In another general aspect, there is provided a method of treatment of malaria. The method includes administering a stable oral solid dosage form comprising; 20 (a) Active compound I; (b) piperaquine; and (c) one or more pharmaceutically acceptable excipients wherein the dosage form is prepared by a dry process. In another general aspect, there is provided a stable solid oral dosage form 25 comprising; (a) 150 mg of Active compound I and (b) 750 mg of piperaquine WO 2013/008218 PCT/IB2012/053614 11 wherein the dosage form is administered once a day for three days. In another general aspect, there is provided a method of treating malaria comprising administering a stable solid oral dosage form comprising; (a) 150 mg Active compound I and 5 (b) 750 mg of piperaquine wherein the dosage form is administered once a day for three days. The details of one or more embodiments are set forth in the description below. Other features, objects and advantages of the invention will be apparent from the description and claims. 10 Detailed Description of the Invention We have now discovered that stable solid oral dosage forms of Spiro or dispiro 1,2,4-trioxolane antimalarials can be prepared which do not degrade significantly and provide acceptable shelf life. The term "stable" as used herein refers to chemical stability of active compound in 15 solid dosage forms against decomposition occurring during shelf life due to hydrolysis, wherein not more than 5% w/w total related substances are formed on storage at 40'C 2'C and 75% ± 5% relative humidity over a period of 6 months. The present invention provides stable solid oral dosage forms of the active compound, by using excipients having low water content and manufactured using dry or 20 non-aqueous formulation processes. The term "active compound" as used herein includes spiro or dispiro 1,2,4 trioxolane compound of structural Formula I 0-O R1 O R2 Formula I 25 wherein R 1 and R 2 are same or different and are selected from hydrogen, substituted or unsubstituted linear or branched alkyl, aryl, and alkaryl groups and substituted or unsubstituted alicyclic groups that are optionally interrupted by one or more oxygen, WO 2013/008218 PCT/IB2012/053614 12 sulfur or nitrogen atoms, substituted or unsubstituted aromatic or heterocyclic groups that may be interrupted by one or more oxygen, sulfur or nitrogen atoms, a hydroxy group, and a halogen, and further providing that the spirocyclohexyl rings attaching R 1 and R 2 are optionally interrupted by one or more oxygen, sulfur, or nitrogen atoms. In particular, it 5 includes compounds of Formula I, wherein Riis hydrogen, for example, compounds of structural Formula II. 0-0 H 0 N H 3 C 0 CH 3 N-H H Formula II Active compound includes one or more of the various spiro and dispiro trioxolane 10 derivatives disclosed in U.S. Application No. 2004/0186168 and U.S. Patent Nos. 6,486,199 and 6,825,230, which are incorporated herein by reference. These trioxolanes are relatively sterically hindered on at least one side of the trioxolane heterocycle which provides better in vivo activity, especially with respect to oral administration. Particularly, spiro and dispiro 1,2,4-trioxolanes derivatives possess excellent potency and efficacy 15 against Plasmodium parasites, and a lower degree of neurotoxicity. The term "Active compound I" herein means cis-adamantane-2-spiro-3'-8'- [[[(2' amino-2'-methylpropyl)amino]carbonyl]-methyl]-1',2',4'-trioxaspiro[4.5]decane hydrogen maleate. The Active compound I may be present in an amount of from about 5% to about 25%, w/w based on the total dosage form. 20 Further, perceiving the potential threat of the malarial parasite developing resistance towards otherwise very potent artemisinin class of drugs, WHO has called for an immediate halt to the provision of single-drug artemisinin malaria pills. In the case of malaria, combination therapy has been applied since around 1990. However, this strategy is being hampered because the Plasmodium parasite has developed resistance, as a result 25 of monotherapy, to certain components of currently applied combination drugs. Combination therapy is expected to retard the development of resistance, improve efficacy WO 2013/008218 PCT/IB2012/053614 13 by lowering recrudescence rate, provide synergistic effect, and increase exposure of the parasite to the drugs. Embodiments of the solid oral dosage of the present invention further include one or more of antimalarial drugs. The antimalarial drugs may include quinine, mefloquine, 5 lumefantrine, sulfadoxine-pyrimethamine, dihydroartimisinin, piperaquine, chloroquine, amodiaquine, proguanil, atovaquone, chloroproguanil, dapsone, fosmidomycin, tetracycline, DB 289 (pafuramidine maleate), clindamycin, or their salts and derivatives thereof. In particular, piperaquine, lumefantrine and DB 289 may be used; however piperaquine remains the preferred one. 10 Selection of combination as an antimalarial therapy is based on certain attributes. Synthetic artemisinin derivatives exhibit their action by their reaction with the iron in free heme molecules in the malaria parasite with the generation of free radicals leading to cellular destruction. On the other hand bisquinoline derivatives such as piperaquine interfere with the detoxification of haemin in the digestive vacuole of the parasite to non 15 toxic malaria pigment, so that haemin can generate free radicals and membrane damage follows. The unrelated mode of action of the two drugs would provide improved therapy, and treatment against all stages of parasites including gametocytes. Additionally, since synthetic artemisinin derivatives are very efficacious and highly potent, these would thereby treat the symptoms quickly, exhibiting fast recovery rates. The combination of 20 synthetic artemisinin derivatives and bisquinoline derivatives such as piperaquine provide a short duration of treatment. Piperaquine is a bisquinoline compound that has antimalarial activity against both P. vivax and P. falciparum, including strains of chloroquine resistant P. falciparum. The tolerability, efficacy, pharmacokinetic profile, low cost and longer-acting piperaquine 25 makes it a very perfect candidate for use in combination with short and rapidly acting Active compound I. Piperaquine of the present invention includes piperaquine phosphate. Piperaquine may be present in an amount of from about 40% to about 80%, w/w based on the total dosage form. The total drug content of the oral dosage forms of the present invention is within 30 the range of about 25% to about 85%, and in particular does not exceed 85% w/w based on the total dosage form.
WO 2013/008218 PCT/IB2012/053614 14 The oral dosage forms of the present invention comprise Active compound I and piperaquine in a weight ratio of about 1:1 to about 1:10. The oral dosage forms of the present invention comprise Active compound I present in a dose range of about 100 mg to about 300 mg and piperaquine present in a dose 5 range of about 700 mg to about 850 mg. The oral dosage forms of the present invention comprise Active compound I present in a unit dose of 100 mg, 150 mg or 250 mg and piperaquine present in a unit dose of 750 mg. The oral dosage forms of the present invention comprise Active compound I in a 10 unit dose of about 100 mg and piperaquine present in a unit dose of about 750 mg. The oral dosage forms of the present invention comprise Active compound I in a unit dose of about 150 mg and piperaquine present in a unit dose of about 750 mg The oral dosage forms of the present invention comprise Active compound I in a unit dose of about 200 mg and piperaquine present in a unit dose of about 750 mg 15 The dosage regimen of the present invention includes administering a fixed dose combination of 150 mg Active compound I and 750 mg of piperaquine once a day for three days. The dose of Active compound I herein means dose equivalent to Active compound I free base. 20 The dosage regimen of the present invention includes three doses over three days. The first dose is administered immediately on diagnosis, the second dose about 24 hours after the first dose, and the third dose about 24 hours after the second dose. The dosage regimen of the present invention is suitable for all patients aged from 12 to 65 years and thus eliminates the need for calculating dose based on individual weight 25 parameters. In the existing artemisinin based combinations, the dose is calculated with respect to the individual weight of the patient and in many cases the tablets are scored to adjust the dose. However, the dosage regimen of this combination is surprisingly simple and effective both for patients and for prescribers.
WO 2013/008218 PCT/IB2012/053614 15 Solid dosage form as used herein is selected from a group consisting of tablets or coated tablets, capsules, pellets, pills, granules and powders. A particularly suitable solid dosage form is that of tablets. Further, it has been observed through exhaustive experimentation that when the 5 active compound is formulated into dosage forms, including liquid as well as solid dosage forms, it gets degraded by hydrolysis. The degradation may be due to water associated with the excipients or added during the course of processing. Thus, liquid oral dosages forms such as aqueous syrups, suspensions or solutions having desired shelf life could not be successfully prepared. Further, preparation of solid oral dosage forms of active 10 compound using techniques involving use of water such as wet granulation, spray drying, or extrusion-spheronization processes resulted in dosage forms with wavering stability results. However, acceptable stability results were obtained when the solid dosage forms were formulated using appropriate excipients with low water content and a process in which water was absent, such as dry granulation, direct compression or non-aqueous 15 granulation. In case where excipients were granulated using water, the excipient granules were dried appropriately before blending with the active compound as such or with active compound containing granules, and processed into solid dosage forms of acceptable stability. The role of excipients and water content was evaluated by conducting 20 compatibility studies of the active compound with various excipients in different proportions, and evaluating the extent of degradation by forced degradation at 60 0 C over the period of 2 weeks and at 50 0 C for 4 weeks. The water content was analyzed using Karl Fischer method and the total related substances (% w/w) were determined by HPLC method. The results of the study are represented below in Table 1. 25 WO 2013/008218 PCT/IB2012/053614 16 Table 1: Compatibility studies of active compound (Active compound I) with various excipients Total Related Substance Water (Percent w/w) Excipient Drug: (%w/w) Initial After 4 After 2 Excipient weeks/ weeks/ 50 0 C 60 0 C Croscarmellose sodium 1:0.5 0.59 0.09 0.34 0.35 Cross povidone 1:0.5 3.49 0.13 0.40 0.68 Sodium starch glycolate 1:0.5 1.43 0.13 0.43 0.89 Hydroxypropyl 1:0.5 1.22 0.17 0.70 1.05 methylcellulose 5cps Polyvinyl pyrrolidone K 30 1:0.5 3.02 0.00 0.33 0.79 Sodium lauryl sodium 1:0.5 0.79 0.15 0.92 1.59 Opadry@ 1:0.5 0.46 0.17 1.85 0.96 Titanium dioxide 1:0.5 0.18 0.16 0.57 0.93 Talc 1:0.1 0.12 0.15 0.63 0.90 Mg. Stearate 1:0.1 0.46 0.13 0.65 0.86 Aerosol 1:0.1 0.27 0.14 0.66 0.86 Polyethylene glycol 400 1:0.1 0.88 0.14 0.66 0.68 Microcrystalline cellulose 1:2 3.69 0.19 0.70 0.74 Starch 1:2 4.73 0.08 0.60 0.74 Dicalcium phosphate 1:2 2.01 0.07 0.77 1.32 Pearlitol 1:2 0.02 0.14 0.72 0.77 Micro crystalline cellulose 1:10 4.94 0.39 0.78 1.02 Starch 1:10 - 0.07 0.60 4.13 Dicalcium phosphate 1:10 2.14 0.17 0.61 6.07 Pearlitol 1:10 0.52 0.14 0.46 0.70 The study clearly indicates the importance of use of excipients having low water or 5 moisture content in stabilizing solid dosage forms of the active compound. In the present invention, we have discovered that the use of excipients having water content less than 6.5% w/w surprisingly increases the stability of the active compound, and thus provides reasonably long shelf lives. Starch was found to be incompatible with the active compound when used in higher amounts. Further, lactose was also found to be 10 incompatible due to degradation by other mechanisms such as Maillard reaction, and dicalcium phosphate was not preferred due to an increase in related substances at 60'C.
WO 2013/008218 PCT/IB2012/053614 17 Microcrystalline cellulose, however, gave the most satisfactory results. The stable solid oral dosage forms of the present invention may further comprise one or more pharmaceutically acceptable excipients, which include all physiologically inert excipients used in the art for the preparation of solid dosage forms. Examples include 5 binders, diluents, glidants/lubricants, disintegrants, surfactants, coloring agents, and the like. The excipients may be used either intragranularly or extragranularly, or both. The weight ratio of active compound and excipients in the dosage forms may vary from about 1.5:1 to about 1:30. Examples of binders include methyl cellulose, hydroxypropyl cellulose, 10 hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, agar, tragacanth and sodium alginate, or mixtures thereof. Examples of diluents include cellulose powdered, microcrystalline cellulose, dextrates, dextrins, dextrose excipients, fructose, kaolin, lactitol, mannitol, sorbitol, sucrose, sugar compressible, and sugar confectioners, in particular microcrystalline 15 cellulose. The diluents may be present in an amount from about 10% to about 40% w/w based on the total weight of the dosage form. Further the weight ratio of Active compound I to microcrystalline cellulose may vary from about 1:1 to about 1:5. Examples of disintegrants include clays, celluloses, alginates, gums, cross-linked polymers (such as cross-linked polyvinylpyrrolidone and cross-linked sodium 20 carboxymethylcellulose), sodium starch glycolate, low-substituted hydroxypropyl cellulose and soy polysaccharides, in particular crospovidone. The disintegrant may be present in an amount from about 1% to about 10% w/w based on the total weight of the dosage form. Examples of lubricants or glidants include talc, magnesium stearate, calcium 25 stearate, stearic acid, colloidal silicon dioxide, magnesium carbonate, magnesium oxide, calcium silicate, microcrystalline cellulose, mineral oil, waxes, glyceryl behenate, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, sodium laurylsulfate, sodium stearyl fumarate, and hydrogenated vegetable oils, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, in particular magnesium 30 stearate. The lubricant may be present in an amount from about 1% to about 5%, w/w based on the total weight of the dosage form.
WO 2013/008218 PCT/IB2012/053614 18 Examples of surfactants include both non-ionic and ionic (cationic, anionic and zwitterionic) surfactants suitable for use in sweetener compositions. These include polyethoxylated fatty acids and its derivatives, for example polyethylene glycol 400 distearate, polyethylene glycol--20 dioleate, polyethylene glycol 4-150 mono dilaurate, 5 polyethylene glycol--20 glyceryl stearate; alcohol--oil transesterification products, for example polyethylene glycol--6 corn oil; polyglycerized fatty acids, for example polyglyceryl--6 pentaoleate; propylene glycol fatty acid esters, for example propylene glycol monocaprylate; mono and diglycerides, for example glyceryl ricinoleate; sterol and sterol derivatives; sorbitan fatty acid esters and its derivatives, for example polyethylene 10 glycol--20 sorbitan monooleate, sorbitan monolaurate; polyethylene glycol alkyl ether or phenols, for example polyethylene glycol--20 cetyl ether, polyethylene glycol--10-100 nonyl phenol; sugar esters, for example sucrose monopalmitate; polyoxyethylenepolyoxypropylene block copolymers known as "poloxamer"; ionic surfactants, for example sodium caproate, sodium glycocholate, soy lecithin, sodium stearyl fumarate, 15 propylene glycol alginate, octyl sulfosuccinate disodium, and palmitoyl carnitine. The coloring agents include any FDA approved colors for oral use. The solid dosage forms may further be coated with one or more functional and/or non-functional layers comprising film-forming polymers, and other coating additives. Examples of film-forming polymers include cellulose derivatives such as ethyl 20 cellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, partially hydrolyzed polyvinyl alcohol, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate; waxes such as polyethylene glycol; and methacrylic acid polymers such as Eudragit@ RL and RS. Alternatively, 25 commercially available coating compositions comprising film-forming polymers marketed under various trade names, such as Opadry@, may also be used for coating. The coating additives comprise one or more of plasticizers, glidants or flow regulators, opacifiers and lubricants. The pharmaceutical acceptable excipients and/or film forming polymers and 30 coating additives may be selected to provide an immediate-release profile or a modified release profile.
WO 2013/008218 PCT/IB2012/053614 19 Solid dosage forms of Active compound I may be prepared by densifying Active compound I and one or more excipients, and processing into solid dosage forms. Densification may be carried out using any conventional method known in the art. In particular, granulation or extrusion-spheronization may be used. 5 In one of the embodiments, stable oral tablets of Active compound I may be prepared by a process comprising the steps of blending Active compound I and intragranular portion of a diluent, lubricant, and disintegrant; passing the blend through a roller compactor to form a compact mass; reducing the compact mass into granules of suitable size; blending the granules with extragranular portion of a lubricant, disintegrant, 10 and diluent in a double cone blender; and finally compressing into tablets using suitable tooling. In another embodiment, stable oral tablets of Active compound I may be prepared by a process comprising the steps of blending Active compound I and intragranular portion of a diluent, lubricant, and disintegrant; compressing the blend in a heavy 15 tabletting press to form slugs; reducing the slugs into granules of suitable size; blending the granules with extragranular portion of a lubricant, disintegrant, and diluent in a double cone blender; and finally compressing into tablets using suitable tooling. In another embodiment, stable oral capsules of Active compound I may be prepared by a process comprising the steps of blending Active compound I and 20 intragranular portion of a diluent, lubricant, and disintegrant; passing the blend through a roller compactor to form a compact mass; reducing the compact into granules of a suitable size; blending the granules with extragranular portion of a lubricant in a double cone blender; and finally filling into capsules of a suitable size. In another embodiment, stable oral capsules of Active compound I may be 25 prepared by a process comprising the steps of blending Active compound I and intragranular portion of a diluent, lubricant, and disintegrant; compressing the blend in a heavy tabletting press to form slugs; reducing the slugs into granules of a suitable size; blending the granules with extragranular portion of lubricant in a double cone blender; and finally filling into capsules of a suitable size.
WO 2013/008218 PCT/IB2012/053614 20 In another embodiment, stable oral tablets of Active compound I may be prepared by a process comprising the steps of blending Active compound I, a diluent, a lubricant and a disintegrant; and directly compressing into tablets using suitable tooling. In another embodiment, stable oral capsules of Active compound I may be 5 prepared by a process comprising the steps of blending Active compound I, a diluent, and a lubricant; and filling into capsules of a suitable size. In another embodiment, stable oral tablets of Active compound I may be prepared by a process comprising the steps of blending Active compound I and intragranular portion of a diluent, and disintegrant; wet granulating the blend with a non aqueous 10 granulating fluid or a solution/dispersion of pharmaceutically acceptable excipients in the non-aqueous granulating fluid; drying and reducing the granules to a suitable size, blending the granules with extragranular portion of a lubricant, disintegrant and diluent in a double cone blender; and finally compressing into tablets using suitable tooling. In yet another embodiment, stable oral capsules of Active compound I may be 15 prepared by a process comprising the steps of blending Active compound I and intragranular portion of diluent, and disintegrant; wet granulating the blend with a non aqueous granulating fluid or a solution/dispersion of pharmaceutically acceptable excipients in the non-aqueous granulating fluid; drying and reducing the granules to a suitable size; blending the granules with extragranular portion of lubricant in a double 20 cone blender; and finally filling into capsules of a suitable size. Examples of non-aqueous granulating fluid include organic solvents such as methanol, ethanol, isopropyl alcohol, dichloromethane, acetone, or mixtures thereof. In yet another embodiment, tablets prepared by any of the above described processes may further be coated with film-forming polymers and one or more coating 25 additives, using techniques well known in the art such as spray coating in a conventional coating pan or a fluidized bed processor or dip coating. Alternatively, coating can also be performed using a hot melt technique. The coating layers over the tablet may be applied as a solution/dispersion of coating components in a suitable solvent. Examples of solvents used for preparing a 30 solution/dispersion of the coating ingredients include methyl alcohol, ethyl alcohol, WO 2013/008218 PCT/IB2012/053614 21 isopropyl alcohol, n-butyl alcohol, acetone, acetonitrile, chloroform, methylene chloride, water and the like, and mixtures thereof. In still another embodiment, one or more of another antimalarial drug selected from piperaquine, lumefantrine, and DB 289 (pafuramidine maleate) may be added in the 5 blend comprising active compound, in any of the embodiments above. The dosage form of the present invention is processed and stored at a temperature below 27'C and relative humidity 50%. The invention described herein is further illustrated by the following examples, which should not be construed as limiting the scope of the invention. 10 EXAMPLES Example 1: Ingredients Percent w/w Intragranular Maleate salt of a compound of Formula II (active 43.2 compound) [Active compound I] Microcrystalline Cellulose 46.67 Magnesium stearate 0.75 Extragranular Microcrystalline Cellulose 5.63 Croscarmellose sodium 3.0 Magnesium stearate 0.75 Total Percentage 100% Coating Opadry@ OY SS 58910 white 2.5 Water q.s Total weight 615 Water content <6.55% w/w Procedure: 1. Active compound I and intragranular portion of microcrystalline cellulose were 15 sieved through sieve BSS #44 and mixed together in a double cone blender to form a uniform blend. 2. To the blend of step 1, intragranular portion of sifted magnesium stearate was added and blended for about 5 minutes.
WO 2013/008218 PCT/IB2012/053614 22 3. The blend of step 2 was compacted in a roller compactor and was sifted through sieve BSS #22 to form granules. 4. Extragranular portion of microcrystalline cellulose, croscarmellose sodium and magnesium stearate were sieved through sieve BSS # 44 and blended with the granules of 5 step 3. 5. The blend of step 4 was compressed using suitable size punches to obtain compressed tablets. 6. The tablets as obtained from step 5 were coated with Opadry@ using conventional coating techniques. 10 The tablets prepared as per Example 1 were subjected to stability studies at 25 0 C/ RH 60%, 30 0 C/RH 65% and 40 0 C/RH 75% over a period of 6 months. The results are summarized in Table 2. The results of in vitro drug release analyzed at predetermined time periods are given in Table 3. Table 2: Total related substances* (Percent w/w) Storage Condition Initial 1 month 2 months 3 months 6 months 25 0 C and 60% relative 0.11
-
- 0.27 0.28 humidity 30 0 C and 65% relative 0.11 0.37 0.27 0.29 0.34 humidity 40 0 C and 75% relative 0.11 0.55 0.67 1.40 1.82 humidity 1 1 15 * % Total Related Substance should not be more than 5% w/w. Table 3: Percentage (%) of In vitro drug release in USP II apparatus* (media: 2% tween 80 in water, 900ml 75 rpm, in 45 min) Storage Condition Initial 1 month 2 months 3 months 6 months 25 0 C and 60% relative 93 -
-
101 95 humidity 30 0 C and 65% relative 93 98 93 94 96 humidity Temperature 40 0 C and 93 98 96 92 94 75% relative humidity _ I I I I *The in vitro drug release (%w/w) should not be less than 7 0% (Q) of the labeled amount 20 dissolved in 45 minutes.
WO 2013/008218 PCT/IB2012/053614 23 As evident from the above studies, the tablets prepared by the process of the present invention in which water is absent shows acceptable shelf stability. Example 2: Ingredients Percent w/w Maleate salt of a compound of Formula II 44.33 (active compound) [Active compound I] Microcrystalline Cellulose 51.17 Magnesium stearate 1.5 Croscarmellose sodium 3.0 Total weight 600 mg Water content <6.5% 5 Procedure: 1. Active compound I, microcrystalline cellulose, croscarmellose sodium and magnesium stearate were sifted through sieve BSS #44. 2. Sifted Active compound I, microcrystalline cellulose, and croscarmellose sodium 10 were mixed in a double cone blender for about 15 minutes to form a uniform blend. 3. To the blend of step 2, sifted magnesium stearate was added and mixed for about 5 minutes. 4. The blend obtained in step 3 was directly compressed using suitable size capsule shape punches to obtain compressed tablets. 15 WO 2013/008218 PCT/IB2012/053614 24 Examples 3 and 4: Ingredients Example 3 Example 4 Percent w/w Percent w/w Intragranular Maleate salt of a compound of Formula II (active 7.68 13.80 compound) [Active compound I] Piperaquine phosphate 61.80 55.50 Microcrystalline Cellulose 20.39 21.15 Magnesium stearate 0.44 0.39 Crospovidone 2.21 1.99 Extragranular Microcrystalline Cellulose 4.32 3.99 Crospovidone 2.11 1.99 Magnesium stearate 1.05 1.19 Total percentage 100% 100% Coating Opadry@ 02B53782 orange 2.5 2.5 Water q.s q.s Total weight (mg) 1332.5 738 Water content <6.55% w/w <6.55% w/w Procedure: 1. Active compound I, piperaquine phosphate and intragranular portion of 5 microcrystalline cellulose and crospovidone were sieved through sieve BSS # 44 and mixed together in a double cone blender to form a uniform blend. 2. To the blend of step 1, intragranular portion of sifted magnesium stearate was added and blended for about 5 minutes. 3. The blend of step 2 was compacted in a roller compactor and was sifted through 10 sieve BSS # 18 to form granules. 4. Extragranular portion of microcrystalline cellulose and crospovidone were sieved through sieve BSS # 44 and blended with the granules of step 3. 5. Extragranular portion of magnesium stearate was sieved through sieve BSS # 44 and blended with the blend of step 4 in a double cone blender for about 5 minutes. 15 6. The blend of step 5 was compressed using suitable size punches to obtain compressed tablets.
WO 2013/008218 PCT/IB2012/053614 25 7. The tablets as obtained from step 6 were coated with Opadry@ using conventional coating techniques and weight built of up to 2.5% w/w. The tablets prepared as per the Example 3 & 4 were subjected to stability studies at 40 0 C/RH 75% over a period of 3 months, as represented in Table 4. 5 Table 4: Percent total related substances* (%w/w) Ingredient Initial 1 2 3 month months months Maleate salt of a compound of Example 3 0.19 0.27 0.44 0.54 Formula II [Active compound I] Example 4 0.25 0.32 0.45 0.54 Example 3 1.16 1.1 1.11 1.16 Piperaquine phosphate Example 4 1.15 1.03 1.13 1.16 * % Total related substance should not be more than 5% w/w. Example 5: Ingredients Percent w/w Intragranular Active compound I 14.60 Piperaquine phosphate 56.30 Microcrystalline Cellulose 16.70 Magnesium stearate 0.43 Crospovidone 2.15 Extragranular Microcrystalline Cellulose 4.30 Crospovidone 2.15 Magnesium stearate 0.97 Coating Opadry@ 02B53782 orange 2.40 Water q.s Total weight (mg) 1332.0 Water content <6.55% w/w 10 WO 2013/008218 PCT/IB2012/053614 26 Procedure: 1. Active compound I, piperaquine phosphate and intragranular portion of microcrystalline cellulose and crospovidone were sieved through sieve BSS # 44 and mixed together. 5 2. To the blend of step 1, intragranular portion of sifted magnesium stearate was added and blended for about 5 minutes. 3. The blend of step 2 was compacted and compacts were sifted through sieve BSS # 18 to form granules. 4. Extragranular portion of microcrystalline cellulose and crospovidone were sieved 10 through sieve BSS # 44 and blended with the granules of step 3. 5. Extragranular portion of magnesium stearate were sieved through sieve BSS # 44 and blended with the blend of step 4 in a double cone blender for about 5 minutes. 6. The blend of step 5 was compressed using suitable size punches to obtain compressed tablets. 15 7. The tablets as obtained from step 6 were coated with Opadry@ using conventional coating techniques and weight built of up to 2.4%w/w. Table 5: Percentage (% w/w) of In vitro drug release of Active compound I, from example 5, in USP II apparatus* (media: 2% tween 80 in water, 900ml, 75 rpm) Time (minutes) (Percent w/w) 15 88 30 87 45 90 20 *The in vitro drug release (% w/w) should not be less than 70% (Q) of the labeled amount dissolved in 45 minutes. A Phase II, double blind, parallel group, randomized, dose finding study was performed to determine the safety and efficacy of three dose levels (50 mg, 100 mg and 200 mg) of Active compound I administered for three days in patients with uncomplicated 25 P. falciparum malaria. Preliminary data showed that the mean parasite clearance time for the patient on 50 mg was 52 hours, and all the 3 patients who were followed up for 28 WO 2013/008218 PCT/IB2012/053614 27 days showed reappearance of parasites. Patients receiving 100 mg had a parasite clearance time of 46.6 hours and 5 of total 6 patients showed reappearance of parasites. Patients receiving 200 mg had a parasite clearance time of 30.4 hours and 4 out of 5 patients showed adequate clinical and parasitological response (ACPR) at day 28. Only 1 patient 5 showed reappearance of parasites. The results obtained so far indicate that Active compound I was a short-acting drug and produced rapid clearance of parasites. The relatively high rate of recrudescence with Active compound I after three days of monotherapy highlighted the need to combine the drug with a long-acting drug. Piperaquine phosphate was chosen as a partner drug and a Phase I double blind, 10 randomized, parallel group, placebo controlled study was conducted in young healthy male subjects to investigate the safety, tolerability and pharmacokinetic profile of Active compound I and piperaquine phosphate after co-administration of multiple oral doses. The study comprised of three cohorts. Cohort I received an oral daily dose of 100 mg of Active compound I and 750 mg of piperaquine phosphate, Cohort II received an oral daily dose of 15 200 mg of Active compound I and 750 mg of piperaquine phosphate and Cohort III received an oral daily dose of 200 mg of Active compound I and 1000 mg of piperaquine phosphate. All three doses were administered once daily for three days in each cohort. No drug related adverse event was observed up to dose levels of 200 mg Active compound I and 750 mg of piperaquine phosphate. However, somnolence and vomiting were reported 20 in dose level of 200 mg Active compound I and 1000 mg of piperaquine phosphate. Systemic exposures to Active compound I after repeated dosing was not appreciably different to that after single dose, hence no accumulation was observed for Active compound I upon 3 days repeated dosing of Active compound I - piperaquine phosphate combination. Exposures of Active compound I increased in a dose-proportional manner 25 upon doubling the dose from 100 mg to 200 mg, when the dose of piperaquine phosphate was kept constant (Table 6).
WO 2013/008218 PCT/1B2012/053614 28 0-oc' om C0 1C o oCo : C 0 C cr 0 o QCc 0 0 7t ci WO 2013/008218 PCT/IB2012/053614 29 Comparative Bioavailability Study of fixed-dose combination of Active compound I 150 mg + piperaquine phosphate 750 mg and co-pack formulations. A single-dose, two-treatment, parallel design study comparing the bioavailability of fixed dose combination tablets of Active compound 1 150 mg + piperaquine phosphate 5 750 mg with co-administered Active compound 1 150 mg and piperaquine phosphate 750 mg was conducted as an open label, balanced, randomized, single-dose, two-treatment, parallel design in 36 healthy, adult, human, male subjects under fasting conditions. The pharmacokinetic parameters are presented in Tables 7 and 8. The results of this study suggested that the pharmacokinetics of Active compound I remained unaltered when 10 administered in fixed-dose combination with piperaquine phosphate as compared to their co-administration as individual tablets. Table 7: Geometric mean pharmacokinetic parameters of Active compound I (free base) following administration of fixed-dose combination (FDC) and co-pack formulations of Active compound I and piperaquine phosphate to young healthy 15 male subjects. Tmax (h) Cmax (ng/ml) AUCO- 24 (ng.h/ml) AUCo-t T 1
/
2 (h) (ng.h/ml) FDC Co- FDC Co- FDC Co- FDC Co- FDC Co pack pack pack pack pack 3.38 3.84 127.73 116.98 1143.01 1100.39 1146.70 1113.48 3.98 3.91 FDC: Fixed-dose combination tablet of Active compound 1 150 mg and piperaquine phosphate 750 mg as one tablet (n= 16); Co-pack: Three Active compound I 50 mg tablets and one piperaquine phosphate 750 mg tablet as individual tablets (n=17), AUCo-t= AUC 0 to last measurable concentration (sampling up to 96 h). 20 Table 8: Geometric mean pharmacokinetic parameters of piperaquine following administration of fixed-dose combination (FDC) and co-pack formulations of Active compound I and piperaquine phosphate to young healthy male subjects. Tmax (h) Cmax (ng/ml) AUCO- 2 4 (ng.h/ml) AUCo-t (ng.h/ml) FDC Co-pack FDC Co-pack FDC Co-pack FDC Co-pack 4.59 4.46 92.68 95.90 728.79 915.19 1431.48 1747.66 FDC: Fixed-dose combination tablet of Active compound 1 150 mg and piperaquine phosphate 750 mg as one tablet (n= 16); Co-pack: Three Active compound I, 50 mg tablets WO 2013/008218 PCT/IB2012/053614 30 and one piperaquine phosphate 750 mg tablet as individual tablets (n=17), AUCo-t= AUC 0 to last measurable concentration (sampling up to 96 h). While several particular compositions have been described, it will be apparent that various modifications and combinations of the compositions detailed in the text can be 5 made without departing from the spirit and scope of the invention.
Claims (24)
1. A stable solid oral dosage form comprising;
(a) cis-adamantane-2-spiro-3'-8'-[[[(2'-amino-2'- methylpropyl)amino]carbonyl]-methyl]- r,2',4'-trioxaspiro[4.5]decane hydrogen maleate (Active compound I);
(b) piperaquine; and
(c) one or more pharmaceutically acceptable excipients; wherein the dosage form is prepared by a dry process.
2. The stable solid oral dosage form according to claim 1, wherein the dosage form comprises:
(a) Active compound I in an amount of from about 5% to about 25%; and (b) piperaquine in an amount from about 40% to about 80%, w/w based on the total weight of the dosage form.
3. The stable solid oral dosage form according to claim 1, wherein the
pharmaceutically acceptable excipient is selected from the group consisting of binders, diluents, glidants/lubricants, disintegrants, surfactants and coloring agents.
4. The stable solid oral dosage form according to claim 3, wherein the diluent is microcrystalline cellulose.
5. The stable solid oral dosage form according to claim 1, wherein the dosage form has dissolution performance such that, more than 70% w/w of the Active compound I dissolves within 45 minutes, in a pH 4.5 acetate buffer with 2% tween 80, in USP type II apparatus.
6. The stable solid oral dosage form according to claim 1, wherein the Active compound I and piperaquine are present in a weight ratio of from about 1 : 1 to about 1 : 10.
7. The stable solid oral dosage form according to claim 1, wherein the Active compound I is present in a dose range of about 100 mg to about 300 mg and piperaquine present in a dose range of about 700 mg to about 850 mg.
8. The stable solid oral dosage form according to claim 1, wherein the dosage form comprises: (a) Active compound I in an amount of from about 5% to about 25%;
(b) piperaquine in an amount of from about 40% to about 80%;
(c) diluent in an amount of from about 10% to about 40%;
(d) disintegrant in an amount of from about 1% to about 10%; and
(e) lubricant in an amount of from about 1% to about 5%, w/w based on the total weight of the dosage form.
9. The stable solid oral dosage form according to claim 1 , wherein the dosage form comprises:
(a) Active compound I;
(b) piperaquine;
(c) microcrystalline cellulose;
(d) crospovidone; and
(e) magnesium stearate.
10. The stable solid oral dosage form according to claim 1 , wherein the dosage form comprises:
(a) Active compound I in an amount of from about 5% to about 25%;
(b) piperaquine in an amount of from about 40% to about 80%, and
(c) microcrystalline cellulose in an amount of from about 10% to about 40%; w/w based on the total weight of the dosage form.
1 1. The stable solid oral dosage form according to claim 1 , wherein the dosage form comprises Active compound I and microcrystalline cellulose in a weight ratio of from about 1 : 1 to about 1 :5.
12. The stable solid oral dosage form according to claim 1 , wherein the dosage form is selected from a group consisting of tablet, capsule, pill, granule and powder.
13. The stable solid oral dosage form according to claim 12, wherein the tablet is coated with one or more functional and or non- functional coating layers comprising film- forming polymers and coating additives.
14. The stable solid oral dosage form according to claim 13, wherein the coating additives comprise one or more of plasticizers, glidants or flow regulators, opacifiers and lubricants.
15. The stable solid oral dosage form according to claim 1 , wherein the dosage form is processed and stored at a temperature below 27°C and relative humidity 50%.
16. The stable solid oral dosage form according to claim 1 , wherein the dry process comprises direct compression or dry granulation.
17. The stable solid oral dosage form according to claim 1 , wherein the dosage form is prepared by a process comprising the steps of:
(a) blending Active compound I, piperaquine, and one or more intragranular excipients;
(b) milling, grinding or sieving the blend by roller compaction to form granules;
(c) blending the granules with one or more extragranular excipients; and (d) compressing the blend into tablets or filling into capsules.
18. The stable solid oral dosage form according to claim 1 , wherein the dosage form is prepared by a process comprising the steps of:
(a) blending Active compound I, piperaquine, and one or more intragranular excipients;
(b) granulating the blend by slugging;
(c) blending the granules with one or more extragranular excipients; and (d) compressing the blend into tablets or filling into capsules.
19. The stable solid oral dosage form according to claim 1 , wherein the dosage form is prepared is prepared by a process comprising the steps of:
(a) blending Active compound I, piperaquine, and one or more
pharmaceutically acceptable excipients; and
(b) directly compressing the blend into tablets or filling into capsules.
20. The stable solid oral dosage form according to claim 1, wherein the dosage form is prepared by a process comprising the steps of:
(a) granulating a blend of one or more excipients;
(b) drying the excipient granules;
(c) blending excipient granules with Active compound I and piperaquine; and (d) compressing the blend into tablets or filling into capsules.
21. A stable solid oral dosage form comprising:
(a) 150 mg of Active compound I and
(b) 750 mg of piperaquine,
wherein the dosage form is administered once a day for three days.
22. The stable solid oral dosage form according to claim 21, wherein the first dose of the dosage form is administered immediately on diagnosis, the second dose about 24 hours after the first dose, and the third dose about 24 hours after the second dose.
23. A method of treatment of malaria, the method comprising administering a stable oral solid dosage form comprising:
(a) Active compound I;
(b) piperaquine; and
(c) one or more pharmaceutically acceptable excipients
wherein the dosage form is prepared by a dry process.
24. A method of treating malaria comprising administering a stable solid oral dosage form comprising;
(a) 150 mg Active compound I and
(b) 750 mg of piperaquine
wherein the dosage form is administered once a day for three days.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/183,119 | 2011-07-14 | ||
US13/183,119 US8664265B2 (en) | 2005-05-18 | 2011-07-14 | Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials |
IN2703DE2011 | 2011-09-19 | ||
IN2703/DEL/2011 | 2011-09-19 | ||
IN2156DE2012 | 2012-07-12 | ||
IN2156/DEL/2012 | 2012-07-12 | ||
PCT/IB2012/053614 WO2013008218A1 (en) | 2011-07-14 | 2012-07-13 | Stable dosage forms of arterolane and piperaquine |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2012282077A1 true AU2012282077A1 (en) | 2014-01-30 |
Family
ID=47505579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012282077A Abandoned AU2012282077A1 (en) | 2011-07-14 | 2012-07-13 | Stable dosage forms of arterolane and piperaquine |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2731603A1 (en) |
JP (1) | JP2014522856A (en) |
KR (1) | KR20140053169A (en) |
CN (1) | CN103930107A (en) |
AP (1) | AP2014007413A0 (en) |
AU (1) | AU2012282077A1 (en) |
CA (1) | CA2850089A1 (en) |
EA (1) | EA201490233A8 (en) |
MX (1) | MX2014000463A (en) |
WO (1) | WO2013008218A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2015008748A0 (en) | 2013-02-28 | 2015-09-30 | Sun Pharmaceutical Ind Ltd | Stable dispersible formulation of arterolane maleate and piperaquine and process of preparation thereof |
KR101698003B1 (en) * | 2016-06-20 | 2017-01-19 | 여오영 | Injectable composition for topical administration for cancer treatment that comprising a quinine salt suspension |
AU2018385363B2 (en) * | 2017-12-12 | 2024-06-13 | Intervet International B.V. | Implantable isoxazoline pharmaceutical compositions and uses thereof |
CN116322688A (en) * | 2020-08-14 | 2023-06-23 | 太阳制药工业有限公司 | Fixed dose combination for the treatment of malaria |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486199B1 (en) | 2001-06-21 | 2002-11-26 | Medicines For Malaria Venture Mmv International Centre Cointrin | Spiro and dispiro 1,2,4-trioxolane antimalarials |
US6906205B2 (en) | 2002-06-21 | 2005-06-14 | Medicines For Malaria Venture Mmv | Spiro and dispiro 1,2,4-trioxolane antimalarials |
US6825230B2 (en) | 2002-06-21 | 2004-11-30 | Medicines For Malaria Venture Mmv | Spiro and dispiro 1,2,4-trixolane antimalarials |
HUE033191T2 (en) * | 2005-05-18 | 2017-11-28 | Sun Pharmaceutical Ind Ltd | Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials |
WO2007132438A2 (en) * | 2006-05-17 | 2007-11-22 | Ranbaxy Laboratories Limited | Antimalarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative |
-
2012
- 2012-07-13 CA CA2850089A patent/CA2850089A1/en not_active Abandoned
- 2012-07-13 WO PCT/IB2012/053614 patent/WO2013008218A1/en active Application Filing
- 2012-07-13 AU AU2012282077A patent/AU2012282077A1/en not_active Abandoned
- 2012-07-13 JP JP2014519689A patent/JP2014522856A/en active Pending
- 2012-07-13 CN CN201280044576.7A patent/CN103930107A/en active Pending
- 2012-07-13 EP EP12743776.2A patent/EP2731603A1/en not_active Withdrawn
- 2012-07-13 EA EA201490233A patent/EA201490233A8/en unknown
- 2012-07-13 KR KR1020147003043A patent/KR20140053169A/en not_active Application Discontinuation
- 2012-07-13 MX MX2014000463A patent/MX2014000463A/en unknown
- 2012-07-13 AP AP2014007413A patent/AP2014007413A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2731603A1 (en) | 2014-05-21 |
AP3777A (en) | 2016-08-31 |
WO2013008218A1 (en) | 2013-01-17 |
JP2014522856A (en) | 2014-09-08 |
EA201490233A1 (en) | 2014-07-30 |
MX2014000463A (en) | 2014-07-09 |
EA201490233A8 (en) | 2015-01-30 |
CN103930107A (en) | 2014-07-16 |
KR20140053169A (en) | 2014-05-07 |
AP2014007413A0 (en) | 2014-02-28 |
CA2850089A1 (en) | 2013-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8664265B2 (en) | Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials | |
JP4803686B2 (en) | Granules and orally disintegrating tablets containing a bitter-tasting drug | |
KR101378973B1 (en) | Composite formulation comprising multi-unit spheroidal tablet(must) encapsulated in a hard capsule and method for preparing the same | |
RU2328274C2 (en) | Medicinal agent lamotrigin with regulated release | |
RU2376988C2 (en) | Pharmaceutical composition of slow release, containing aplindor and its derivatives | |
KR102072546B1 (en) | Oral tablet formulation of lenalidomide | |
JP6288158B2 (en) | Oral preparation with improved quality | |
US5814339A (en) | Film coated tablet of paracetamol and domperidone | |
KR101828630B1 (en) | Orally disintegrating tablet | |
AU2012282077A1 (en) | Stable dosage forms of arterolane and piperaquine | |
WO2010023690A2 (en) | Prolonged release formulation of amisulpride | |
WO2005023304A2 (en) | Antimalarial compositions and manufacturing process thereof | |
EP2698150A1 (en) | Oral solid preparation of compound antituberculosis drug and preparation method thereof | |
EP3496719B1 (en) | A multi-class anti-retroviral composition | |
KR20140081826A (en) | Sustained-release preparation | |
AU2020286220B2 (en) | An orally disintegrating pharmacutical composition comprising nefopam and process for preparing the same | |
WO2007017646A2 (en) | Anti-malarial composition comprising artesunate and lumefantrine | |
KR102127625B1 (en) | Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition | |
OA16845A (en) | Stable dosage forms of arterolane and piperaquine | |
WO2014132226A1 (en) | Stable dispersible formulation of arterolane maleate and piperaquine and process of preparation thereof | |
WO2022074681A1 (en) | Pharmaceutical compositions with enhanced blend uniformity and content uniformity | |
KR100212960B1 (en) | Complex preparation for oral use | |
KR20180002437A (en) | Pharmaceutical complex formulation comprising doxylamine and pyridoxine | |
KR20160034982A (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ENOSE, ARNO APPAVOO; MADAN, HARISH KUMAR; MADAN, SUMIT; TREHAN, ANUPAM; TYAGI, PUNEET; ARORA, VINOD KUMAR; BHATTACHARYYA, SANJUKTA; ROY, ARJUN AND ANNAMDEVARA, BALAJI |
|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |